Entering the ‘battle’ between precision and evidence-based medicine

+Clinical
In print

Entering the ‘battle’ between precision and evidence-based medicine

Jo Scott-Jones

Jo Scott-Jones

battle Russia
Are GPs ready to wrestle with evidence-based and precision medicine?

Comprehensive information about specific gene variants and their impact on diagnosis and treatment is now available in an easily searchable database – it’s time to get to grips with genomics

Of patients who experience allopurinol-induced severe cutaneous adverse reactions (SCAR), 25–30 per cent die
References

1. Taylor C. ‘A battle is looming’ - GP urges docs to join the genomics revolution.  www.nzdoctor.co.nz/article/news/battle-looming-gp-urges-docs-join-genomics-revolution 

2. Medsafe. Pharmacogenomics – helps reduce rash decisions. Prescriber Update 2018:39(2);25–27. https://bit.ly/2M4k9kR  

3. Whirl-Carrillo M, McDonagh EM, Hebert JM et al. Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther 2012;92(4):414–17. 

4. Rademaker M. Drug hypersensitivity syndrome. DermNet NZ 2004, updated 2016. www.dermnetnz.org 

5. Keller SF, Lu N, Blumenthal KG et al. Racial/ethnic variation and risk factors for allopurinol-associated severe cutaneous adverse reactions: a cohort study. Ann Rheum Dis 2018; doi: 10.1136/annrheumdis-2017-212905 (Epub ahead of print) 

 

Comments

Precision medicine and personalised healthcare will eventually eclipse EBM. It is not a battle between the two, it is the evolution from one to another.

Joe, wouldn't you be better, given that we can't do the HLAB5801 test, to use the age, gender and renal function decision criteria when prescribing allopurinol in PI patients?